Announcements Trials

Browse Landscape

Phase

Phase NA 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Vomiting 9 Nausea 5 Breast Neoplasms 4 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Myeloproliferative Disorders 1 Multiple Myeloma 1 Leukemia, Myeloid, Acute 1 Inflammatory Breast Neoplasms 1 Hematologic Neoplasms 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1

Interventions

ruxolitinib 6 Peripheral Blood Stem Cell Transplantation 5 Mycophenolic Acid 5 Cytarabine 5 fludarabine phosphate 4 Whole-Body Irradiation 4 Methotrexate 4 Daunorubicin 4 Thioguanine 3 Tacrolimus 3 Etoposide 3 Early Intervention, Educational 3 Cyclophosphamide 3 ponatinib 2 parsaclisib 2 nilotinib 2 merphos 2 luspatercept 2 fludarabine 2 fedratinib 2 anagrelide 2 Tretinoin 2 Therapeutics 2 Psychiatric Rehabilitation 2 Mitoxantrone 2 Filgrastim 2 Cyclosporins 2 Cyclosporine 2 Busulfan 2 Asparaginase 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Myeloproliferative Disorders × Aprepitant × Clear all

NCT03808805 2025-12-03

APHYPAP

University Hospital, Brest

Phase 3 Completed

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡